Prospect: information for the patient
Mercaptopurina Silver 50 mg tablets
Read this prospect carefully before starting to take this medicine,because it contains important information for you.
-This medicine has been prescribedonlyto you, and you must not give it to other people even iftheyhave the same symptomsas you,as it may harm them.
1.What is Mercaptopurina Silver and what is it used for
2.What you need to know beforestartingto take Mercaptopurina Silver
3.How to take Mercaptopurina Silver
4.Possible adverse effects
5Storage of Mercaptopurina Silver
6 Contents of the package and additional information
Mercaptopurina Silver contains an active ingredient called mercaptopurine monohydrate.It belongs to a group of medicines called cytotoxics (also known as chemotherapy). Mercaptopurine is used to treat leukemia (blood cancer). It works by reducing the number of new blood cells produced by your body.
Mercaptopurine is used for:
Do not take Mercaptopurina Silver:
Warnings and precautions
Consult your doctor or pharmacist before starting to take Mercaptopurina Silver if:
In some patients with inflammatory bowel disease who have received treatment with 6-mercaptopurine, a rare and aggressive type of cancer called T-cell lymphoma of the liver and spleen has appeared (see section 4).
If you are receiving immunosuppressive treatment, taking Mercaptopurina Silver may increase your risk of:
Infections
When receiving treatment with Mercaptopurina Silver, the risk of developing viral, fungal, and bacterial infections is higher, and these infections may be more severe. See also section 4.
Before starting treatment, inform your doctor if you have had or not varicella, herpes, or hepatitis B (a liver disease caused by a virus).
NUDT15 gene mutation
If you have a hereditary mutation in the NUDT15 gene (a gene involved in the breakdown of Mercaptopurina Silver in the body), you have a higher risk of infections and hair loss, and in this case, your doctor may give you a lower dose.
Vitamin B3 deficiency (pellagra)
Inform your doctor immediately if you have diarrhea, localized pigmented rashes (dermatitis), or deterioration of memory, reasoning, and thinking ability (dementia), as these symptoms may indicate a vitamin B3 deficiency. Your doctor will prescribe vitamin supplements (niacin/nicotinamide) to improve your condition.
Taking Mercaptopurina Silver may increase your risk of:
If you are unsure whether any of the above situations applies to you, speak with your doctor, nurse, or pharmacist before taking mercaptopurine.
Taking Mercaptopurina Silver with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including those purchased without a prescription.
In particular, inform your doctor or pharmacist if you are taking any of the following medications:
If you are to be vaccinated while taking mercaptopurine, it is essential to consult with your doctor or nurse beforehand. This is because some vaccines (such as polio, measles, mumps, and rubella) may cause infection if given while taking mercaptopurine.
Taking Mercaptopurina Silver with food and drinks
Mercaptopurine Silver can be taken with food or on an empty stomach. However, the chosen method must be the same every day.
Do not take mercaptopurine with milk or dairy products, as they may reduce the effectiveness of the medication. Mercaptopurine Silver should be taken at least 1 hour before or 3 hours after consuming milk or dairy products.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy:
If you are planning to have a baby, do not take mercaptopurine. This applies to both men and women. Mercaptopurine may be harmful to sperm or eggs. You should take effective contraceptive precautions to avoid pregnancy while you or your partner are taking this medication. Consult your doctor.
If you are already pregnant, inform your doctor before taking mercaptopurine.
Taking Mercaptopurina Silver during pregnancy may cause intense and excessive itching without a skin rash. You may also experience nausea and loss of appetite at the same time, which may indicate a condition called cholestasis of pregnancy (a liver disease during pregnancy). Speak with your doctor immediately, as this condition may cause harm to the fetus.
Breastfeeding:
It is not recommended to breastfeed while taking mercaptopurine. Consult your doctor, pharmacist, or midwife.
Driving and operating machinery
Mercaptopurine is not expected to affect your ability to drive or operate machinery, although no studies have been conducted to confirm this.
Mercaptopurina Silver contains lactose and sodium
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially 'sodium-free'.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist.This medication should be administered exactly as directed.Consult your doctor or pharmacist again if you are unsure.In case of doubt, consult your doctor or pharmacist again.
Mercaptopurina should be administered only by a specialist doctor with experience in treating blood diseases.
The usual initial dose in adults, adolescents, and children is 25-75 mg/m2of body surface area per day. Your doctor will prescribe the correct dose for you. In some cases, your doctor may change your Mercaptopurina Silver dose based on the results of different tests. Consult your doctor or nurse if you have any doubts about the dose you should take.
It is essential to take Mercaptopurina Silver at night for the medication to be more effective.
You can take the medication with food or on an empty stomach, but the chosen method must be the same every day. You should take the medication at least 1 hour before or 2 hours after consuming milk or dairy products.
If you take more Mercaptopurina Silver than you should
If you take more Mercaptopurina Silver than you should, inform your doctor or go to the hospital immediately. You may experience nausea, vomiting, or diarrhea. Carry the medication packaging and this leaflet with you.
In case of overdose, call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Mercaptopurina SilverMercaptopurina Silver
Inform your doctor.
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Mercaptopurina Silver
Do not stop taking your medication unless your doctor instructs you to do so, as you may experience a relapse of your disease.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
If you experience any of the following side effects, consult your specialist doctor or go to the hospital immediately:
Allergic reaction, whose signs may be:
Any sign of fever or infection (sore throat, mouth sores or urinary problems).
Any unexpected hematoma or bleeding, as it could indicate that you are producing an insufficient number of a certain type of blood cells.
If you feel unwellsuddenly(although your temperature is normal), with abdominal pain and nausea, as it could be a sign of pancreatitis inflammation.
Yellow discoloration of the white part of the eyes or skin (jaundice).
If you have diarrhea.
Consult your doctor if you experience any of the following side effects that may also appear with this medicine:
Very frequent may affect more than 1 in 10 people
Frequent: may affect up to 1 in 10 people
Rare: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Very rare: may affect up to 1 in 10,000 people
Other side effects (unknown frequency)
Other side effects in children
-low blood sugar (hypoglycemia); unknown frequency
If you consider that any of the side effects you are experiencing are severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout of the sight and reach of children,preferably in a closed cabinet with a lock.Accidental ingestion can be fatal for children.
Do not usethis medicationafter the expiration date that appears onthe blister pack or in the boxafter CAD:. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. Ask your pharmacist how to dispose of packaging and medications you no longer need. This will help protect the environment.
Composition of Mercaptopurina Silver
- The other components(excipients)are:microcrystalline cellulose, povidone, sodium croscarmellose, lactose monohydrate, magnesium stearate, and stearic acid..
Appearance of the product and content of the packaging
Mercaptopurina Silver are yellowish circular tablets
Packaging size: 24 or 25 tablets.
Only some packaging sizes may be commercially marketed.
In the 24-tablet presentation, Mercaptopurina Silver is packaged in two Alu-PVC or ALU/PVC-PVDC blisters of 12 tablets each, inside a cardboard case.
In the 25-tablet presentation, Mercaptopurina Silver is packaged in a single Alu-PVC or ALU/PVC-PVDC blister of 25 tablets, inside a cardboard case.
Holder of the marketing authorization
SILVER PHARMA S.L.
Avda. Camino de lo Cortao 16
28703 San Sebastian de los Reyes, (Madrid)
Spain
Responsible for manufacturing
Ardena Pamplona, S.L. Pol Mocholi C/ Noáin, 1 31110 Noáin (Navarra) Spain Laboratori Fundació DAU Calle Lletra C, 12-14, Pol. Ind. Zona Franca, 08040 Barcelona, Spain |
Revision date of thisleaflet: August 2024
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.